| |
| |
| |
Centre for Policy on Ageing | |
 | |
|
Memantine in severe dementia
— results of the 9M-BEST Study (Benefit and Efficacy in Severely Demented Patients during Treatment with Memantine) | | Author(s) | B Winblad, N Poritis |
| Journal title | International Journal of Geriatric Psychiatry, vol 14, no 2 [Proceedings of the symposium held in Scotland, June 1998, Part 1], February 1999 |
| Pages | pp 135-146 |
| Keywords | Dementia ; Drugs ; Evaluation ; Clinical surveys. |
| Annotation | Memantine is an uncompetitive N-methyl-D-aspartate (NMDA) antagonist. Its clinical efficacy and safety was assessed in moderately severe to severe primary dementia as defined by DSM-III-R criteria, the Global Deterioration Scale and Mini-Mental State Examination (MMSE). The intention to treat (ITT) sample comprised 166 patients and 151 patients were treated per protocol. At 12-week ITT endpoint analysis, 82 received memantine 10mg per day, 84 placebo. Dementia was in 49% of the Alzheimer type and in 51% of the vascular type. A positive response in the CGI-C (Clinical Global Impression of Change) was seen in 73% versus 45% in favour of memantine, independent of the aetiology of dementia. Results in the BGP (Behavioural Rating Scale for Geriatric Patients) subscore "care dependence" were 3.1 points improvement under memantine, and 1.1 points under placebo. A coincident response of the two independent target variables was observed in 61.3% (memantine) versus 31.6% (placebo). Results of the trial support the hypothesis that memantine treatment leads to functional improvement and reduces care dependence in severely demented patients. (RH). |
| Accession Number | CPA-990825235 A |
| Classmark | EA: LLD: 4C: 3G |
Data © Centre for Policy on Ageing |
|
| ...from the Ageinfo database published by Centre for Policy on Ageing. |
| |
|
|